Clinical trials: Infection Due to Resistant Organism
Infection Due to Resistant Organism
FMT for MDRO Colonization in Solid Organ Transplant
This is a pilot feasibility study to determine whether fecal microbiota transplantation (FMT) can suppress or reverse gastrointestinal carriage of MDROs in hospitalized solid organ transplant recipients with a history of one or…
- Trial name
- FMT (NCT02816437)
- Testing
- OpenBiome Fecal Microbiota Transplantation retention enema
- Sponsor
- University of Miami
Clinically Significant Bacteremia, Organ Transplantation
Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.
Main objective: to observationally assess the efficacy and safety of different antimicrobials in BSI due to ESBL or carbapenemase-producing Enterobacterales in SOT. Secondary objectives: 1.
- Conditions
- Clinically Significant Bacteremia, Organ Transplantation, Infection, Bacteremia
- Trial name
- INCREMENT-SOT (NCT02852902)
- Where
- 3 sites in Spain
- Volunteers
- 820 people
- Sponsor
- Spanish Network for Research in Infectious Diseases
Clinically Significant Bacteremia
Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study
Main objective: to observationally assess the efficacy of different antimicrobials in Bloodstream Infection (BSI) due to Enterobacteriaceae producing ESBLs or carbapenemases.
- Trial name
- INCREMENT (NCT01764490)
- Where
- Spain
- Volunteers
- 1,344 people
- Sponsor
- JESUS RODRIGUEZ BAÑO
Bloodstream Infection, Septic Shock
Bloodstream Infection Due to Multidrug-Resistant Organisms - Multicenter Study on Determinants of Clinical Outcomes
Continual surveillance of both community-acquired and nosocomial bloodstream infections for specific target organisms. Analysis of comorbidities, complications, bacterial resistance patterns, bacterial genomics (e. g.
- Trial name
- BLOOMY-COM (NCT03578835)
- Where
- 6 sites in Germany
- Volunteers
- 6,000 people
- Sponsor
- University Hospital Tuebingen
Infection Due to Resistant Organism
Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
Arbekacin for the use of infection caused by multidrug-resistant organisms
- Trial name
- NCT01659515
- Testing
- Arbekacin Sulfate
- Where
- United States
- Sponsor
- U.S. Army Medical Research and Development Command
Infection Due to Resistant Organism
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Transplant patients are at increased risk of colonization and infection with Multidrug Resistant Organisms (MDROs) due to medications that modify their immune systems, increased healthcare and antibiotic exposure, and surgical…
- Trial name
- PREMIX (NCT02922816)
- Testing
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Urinary Tract Infections
Fecal Microbiota Transplantation (FMT) for MDRO UTI
The purpose of this study is to determine the safety and impact of fecal microbiota transplantation (FMT) on the fecal and urine microbiome, urine metabolome, risk of recurrent urinary tract infection (UTI), and persistent…
- Trial name
- NCT03367910
- Testing
- Fecal microbiota transplant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Gram-Negative Bacterial Infections
Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae…
- Trial name
- NCT00079989
- Testing
- tigecycline
- Volunteers
- 115 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer